TY - JOUR
T1 - Diabetes impairs hematopoietic stem cell mobilization by altering niche function
AU - Ferraro, Francesca
AU - Lymperi, Stefania
AU - Méndez-Ferrer, Simón
AU - Saez, Borja
AU - Spencer, Joel A.
AU - Yeap, Beow Y.
AU - Masselli, Elena
AU - Graiani, Gallia
AU - Prezioso, Lucia
AU - Rizzini, Elisa Lodi
AU - Mangoni, Marcellina
AU - Rizzoli, Vittorio
AU - Sykes, Stephen M.
AU - Lin, Charles P.
AU - Frenette, Paul S.
AU - Quaini, Federico
AU - Scadden, David T.
PY - 2011/10/12
Y1 - 2011/10/12
N2 - Success with transplantation of autologous hematopoietic stem and progenitor cells (HSPCs) in patients depends on adequate collection of these cells after mobilization from the bone marrow niche by the cytokine granulocyte colony-stimulating factor (G-CSF). However, some patients fail to achieve sufficient HSPC mobilization. Retrospective analysis of bone marrow transplant patient records revealed that diabetes correlated with poor mobilization of CD34+ HSPCs. Inmouse models of type 1 and type 2 diabetes (streptozotocin-induced and db/db mice, respectively), we found impaired egress of murine HSPCs from the bone marrow after G-CSF treatment. Furthermore, HSPCs were aberrantly localized in the marrow niche of the diabetic mice, and abnormalities in the number and function of sympathetic nerve termini were associated with this mislocalization. Aberrant responses to β-adrenergic stimulation of the bone marrow included an inability of marrow mesenchymal stem cells expressing the marker nestin to downmodulate the chemokine CXCL12 in response to G-CSF treatment (mesenchymal stem cells are reported to be critical for HSPC mobilization). The HSPC mobilization defect was rescued by direct pharmacological inhibition of the interaction of CXCL12 with its receptor CXCR4 using the drug AMD3100. These data suggest that there are diabetesinduced changes in bone marrow physiology and microanatomy and point to a potential intervention to overcome poor HSPC mobilization in diabetic patients.
AB - Success with transplantation of autologous hematopoietic stem and progenitor cells (HSPCs) in patients depends on adequate collection of these cells after mobilization from the bone marrow niche by the cytokine granulocyte colony-stimulating factor (G-CSF). However, some patients fail to achieve sufficient HSPC mobilization. Retrospective analysis of bone marrow transplant patient records revealed that diabetes correlated with poor mobilization of CD34+ HSPCs. Inmouse models of type 1 and type 2 diabetes (streptozotocin-induced and db/db mice, respectively), we found impaired egress of murine HSPCs from the bone marrow after G-CSF treatment. Furthermore, HSPCs were aberrantly localized in the marrow niche of the diabetic mice, and abnormalities in the number and function of sympathetic nerve termini were associated with this mislocalization. Aberrant responses to β-adrenergic stimulation of the bone marrow included an inability of marrow mesenchymal stem cells expressing the marker nestin to downmodulate the chemokine CXCL12 in response to G-CSF treatment (mesenchymal stem cells are reported to be critical for HSPC mobilization). The HSPC mobilization defect was rescued by direct pharmacological inhibition of the interaction of CXCL12 with its receptor CXCR4 using the drug AMD3100. These data suggest that there are diabetesinduced changes in bone marrow physiology and microanatomy and point to a potential intervention to overcome poor HSPC mobilization in diabetic patients.
UR - http://www.scopus.com/inward/record.url?scp=80054035544&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3002191
DO - 10.1126/scitranslmed.3002191
M3 - Article
C2 - 21998408
AN - SCOPUS:80054035544
SN - 1946-6234
VL - 3
JO - Science translational medicine
JF - Science translational medicine
IS - 104
ER -